View Cart  

Boehringer Completes Phase III Studies of Nintedanib

A A
Boehringer Ingelheim Pharmaceuticals has completed clinical trial enrollment of two Phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120).
Pharmaceutical Business Review